GLP-1 drugs directly affect ovarian cells and improve fertility in PCOS women, but animal studies suggest potential ovarian risks that need further investigation in humans.
GLP-1 drugs improved both IVF and natural conception ratesLiraglutide with metformin significantly improved IVF pregnancy rates in PCOS women, while exenatide increased natural conception rates — but animal studies warn of dose-dependent ovarian and uterine damage.
What the researchers found
GLP-1 receptor agonists directly affect ovarian biology — not just through weight loss, but by acting on ovarian cells themselves. In women with PCOS, these drugs improved menstrual regularity, reduced free testosterone, and increased sex hormone-binding globulin. Liraglutide combined with metformin significantly improved IVF pregnancy rates, while exenatide increased natural conception rates. At the molecular level, GLP-1 receptor activation promotes granulosa cell growth through FOXO1 signaling and modifies steroid hormone production by suppressing key steroidogenic enzymes. However, animal studies raised concerns about potential ovarian and uterine damage at certain doses, including oxidative stress, granulosa cell death, and uterine inflammation.
Why it matters
Millions of women of reproductive age now take GLP-1 drugs, and many have PCOS — a condition where these drugs are increasingly used. This review reveals that GLP-1 drugs do far more than just help with weight loss; they directly influence ovarian function, hormone production, and fertility at the cellular level. The finding that liraglutide improved IVF success rates is clinically significant, but the animal data showing potential ovarian damage raises important safety questions that need answers.
How the study worked
Systematic review following PRISMA guidelines, searching PubMed, Scopus, and Web of Science for randomized trials, prospective studies, animal models, and cellular experiments evaluating GLP-1 receptor agonist effects on reproductive or ovarian outcomes. Data included metabolic changes, androgen levels, menstrual regularity, ovarian structure, granulosa cell biology, signaling pathways, and fertility/IVF outcomes.
Who was studied
Systematic review covering women with PCOS, animal models, and in vitro granulosa cell studies
What this study cannot tell us
Most clinical evidence comes from women with PCOS, so findings may not apply to women without PCOS. Animal studies showed contradictory results (both beneficial and harmful), suggesting dose and context matter significantly. The review acknowledges limited understanding of the molecular mechanisms and calls for controlled human research to clarify reproductive safety, particularly in non-PCOS populations and IVF settings.
How to read the evidence
This is a PRISMA-compliant systematic review integrating clinical trials, animal studies, and cellular experiments. While the clinical evidence for PCOS fertility improvements is promising, it comes from a limited number of trials. The conflicting animal data (both beneficial and harmful effects) and lack of large-scale safety studies temper the overall evidence strength.
When this study was published
Published in 2026, this is a very current systematic review that captures the latest evidence on GLP-1 drugs and reproductive health, a rapidly evolving research area.
The bigger picture
As GLP-1 drugs become the most prescribed medications for obesity and diabetes, understanding their effects on fertility is critical. This review shows these drugs have direct biological effects on the ovaries that go far beyond weight loss — they modify hormone production, cell survival, and follicle development. For the millions of reproductive-age women now taking these drugs, this research highlights both opportunity (improved fertility in PCOS) and concern (potential reproductive toxicity) that demand urgent clinical investigation.
Questions still open
- Should women trying to conceive be prescribed GLP-1 drugs for fertility benefits, or do the animal safety concerns outweigh the potential gains?
- How long before IVF should GLP-1 drugs be stopped to maximize benefits while minimizing ovarian risks?
- Do GLP-1 drugs affect fertility in women without PCOS, and if so, in what direction?
Common questions
Can GLP-1 drugs like Ozempic help women with PCOS get pregnant?
Are GLP-1 drugs safe for women's reproductive systems?
Read the original research
A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms.
International journal of molecular sciences, 27(2)
Citation
Voros, Charalampos; Chatzinikolaou, Fotios; Papapanagiotou, Ioannis; Polykalas, Spyridon; Mavrogianni, Despoina; Koulakmanidis, Aristotelis-Marios; Athanasiou, Diamantis; Kanaka, Vasiliki; Bananis, Kyriakos; Athanasiou, Antonia; Athanasiou, Aikaterini; Papadimas, Georgios; Tsimpoukelis, Charalampos; Vaitsis, Dimitrios; Karpouzos, Athanasios; Daskalaki, Maria Anastasia; Kanakas, Nikolaos; Theodora, Marianna; Thomakos, Nikolaos; Antsaklis, Panagiotis; Loutradis, Dimitrios; Daskalakis, Georgios. (2026). A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms.. International journal of molecular sciences, 27(2). https://doi.org/10.3390/ijms27020759